SCHEMBL29903004

SCHEMBL29903004

CCOC(=O)c1cccn1CCCC(C)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.43
TNF P01375 3/20 0.42
EPHX2 P34913 8/20 0.42
TSHR P16473 1/20 0.40
MEN1 O00255 1/20 0.38
GLA P06280 1/20 0.38
KMT2A Q03164 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
LMNA P02545 1/20 0.38
CYP2C9 P11712 1/20 0.38
GABRA1 P14867 1/20 0.38
CYP2C19 P33261 1/20 0.38
GABRB2 P47870 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23852583 0.89 TNF (0.54) CNR2TNFEPHX2
SCHEMBL23850165 0.89 MEN1 (0.49) CNR2TNFEPHX2TSHRMEN1
SCHEMBL29225350 0.87 EPHX2 (0.44) CNR2EPHX2TSHRCA12CA1
SCHEMBL23852674 0.84 TNF (0.50) CNR2TNFEPHX2
SCHEMBL23850522 0.84 MEN1 (0.45) CNR2TNFEPHX2TSHRMEN1
SCHEMBL3024871 0.84 EPHX2 (0.42) CNR2TNFEPHX2TSHRCA12
SCHEMBL30829444 0.83 TSHR (0.46) EPHX2TSHRCA12CA1CA2
SCHEMBL29225365 0.83 TSHR (0.46) EPHX2TSHRCA12CA1CA2
SCHEMBL3016395 0.81 EPHX2 (0.44) EPHX2TSHRCA12CA1CA2
SCHEMBL13541632 0.80 TSHR (0.48) EPHX2TSHRCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111433207-B As alpha V Pyrrolopyrazine derivatives of integrin inhibitors 百时美施贵宝公司 2023-07-25 CN disclosed
CN-110139864-B Pyrrole amides as alpha V integrin inhibitors 百时美施贵宝公司 2022-08-23 CN disclosed